( mployees in 79 countriesand markets i...)New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir,Health

mployees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

References:

Meneghini L, Koehnen C, Weng W, et al. “The Usage of a Simplified Self-titration Dosing Guideline for Insulin Detemir in Patients Type 2 Diabetes – Results of the 303 Algorithm Study.” Oral presentation (abstract # 197-OR) at: 67th annual meeting of the American Diabetes Association, Chicago, IL, June 23-26, 2007.

Facts on File, Novo Nordisk, Princeton, NJ.

Weight Control Information Network. “Do You Know the Health Risks of Being Overweight?” http://win.niddk.nih.gov/publications/health_risks.htm. Web site accessed May 2007.

For further information, please contact:



Media: Investors:
Media:

An Phan

Tel (on-site): 609-558-0420

Tel (office): 609-987-4893

Christian Qvist Frandsen

Tel (direct): (1) 609 919 7937

cqfr@novonordisk.com

'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea